Prognosis
China’s CoronaVac Trial Resumes in Brazil After ‘Adverse Event’
- Reversal comes amid criticism that the halt was politicized
- Sinovac vaccine has been at center of political feud in Brazil
This article is for subscribers only.
Brazil reversed its decision to suspend trials of a coronavirus vaccine from Chinese developer Sinovac Biotech Ltd., allowing tests to resume less than 48 hours after being halted amid criticism the initial pause was politically motivated.
In a statement posted on its website Wednesday, health agency Anvisa said it initially got “precarious data” on a “grave” event, which led it to suspend the study late Monday. The agency added that it reversed its previous ruling after receiving new information, and that it will keep monitoring the case.